Karl Strpklin's  Instablog

Karl Strpklin
Send Message
  • RBCAA, CHMP, PWRM, HOLX - DoubleInStocks.com Stock Report! Nov 6th 2010 0 comments
    Nov 6, 2010 3:56 PM | about stocks: RBCAA, CHMP, HOLX

    money 1



    PWRM, Power 3 Medical Products Inc., PWRM.OB
    has signed a definitive agreement recently to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger.

    The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

    Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

    Power3 Medical Hits a Grand Slam at ICAD With Four Alzheimer’s Poster Presentations

    Power3 Medical Products, Inc. announced a few weeks ago that it delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

    “In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3’s President and Chief Scientific Officer.

    “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”

    About the Company

    Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.

    Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials.

    These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

    Power3 Medical Product’s Website


    Republic Bancorp, Inc. (NASDAQ:RBCAA) recently reported the Company achieved net income of $60.3 million for the first nine months of 2010, a $22.0 million, or 58%, increase over the first nine months of 2009. Diluted Earnings per Class A Common Share increased 57% for the first nine months of 2010 to $2.89. Return on average assets and return on average equity were 2.25% and 22.50% for the nine months ended September 30, 2010.

    Republic Bancorp, Inc. operates as the holding company for Republic Bank & Trust Company and Republic Bank, which provides banking, tax refund solutions, and mortgage banking services to individuals and businesses in the United States.


    Champion Industries, Inc. (NASDAQ:CHMP) recently announced results for the third quarter of 2010 of a loss of $(571,000) or $(0.06) per share compared to a loss of $(307,000) or $(0.03) per share for the same period in 2009. The results were reflective of restructuring related charges of approximately $1.6 million, or $1.0 million after tax, or $0.10 per share on a basic and diluted basis.

    Champion Industries, Inc., together with its subsidiaries, engages in commercial printing, business forms manufacturing, and office products and furniture supply businesses primarily in the United States.


    Hologic, Inc. (NASDAQ:HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, recently announced the long-term, five-year results from the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial while showcasing the MammoSite ML system at the 52nd ASTRO Annual Meeting that was held in San Diego October 31 through November 4, 2010.

    Hologic, Inc. develops, manufactures, and distributes medical imaging systems, and diagnostic and surgical products for serving the healthcare needs of women.




    Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).

    Sign Up for our FREE Daily Stock Newsletter


    Stocks: RBCAA, CHMP, HOLX
Back To Karl Strpklin's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.